Results 11 to 20 of about 14,161,714 (418)

CRISPR/Cas9-mediated knockin of human factor IX into swine factor IX locus effectively alleviates bleeding in hemophilia B pigs [PDF]

Haematologica, 2020
Hemophilia B is an X-linked recessive bleeding disorder caused by abnormalities in the coagulation factor IX gene. Without prophylactic treatment, patients experience frequent spontaneous bleeding episodes.
Jiahuan Chen, Beiying An, Biao Yu, Xiaohuan Peng, Hongming Yuan, Qiangbing Yang, Xue Chen, Tingting Yu, Lingyu Wang, Xinwei Zhang, He Wang, Xiaodong Zou, Daxin Pang, Hongsheng Ouyang, Xiaochun Tang   +14 more
doaj   +2 more sources

Factor IX levels and oestrogens. [PDF]

BMJ, 1968
A. M. Dickins
openalex   +4 more sources

Peri-operative Management and the Role of Minimally Invasive Spine Surgery in a Case of Hemophilia B [PDF]

Journal of Minimally Invasive Spine Surgery and Technique, 2022
Hemophilia A and B are rare X-chromosome-linked recessive bleeding disorders caused by mutations in the genes causing abnormalities of blood clotting factors VIII and IX, respectively.
VNR Praveen Goparaju, Amit Chugh, Ameya Rangnekar, Vishal Kundnani   +3 more
doaj   +1 more source

Haemophilia specialist nurses’ perceptions of haemophilia B

The Journal of Haemophilia Practice, 2021
Some clinicians believe that haemophilia B is associated with less bleeding than haemophilia A, yet there appears to be little difference in health-related outcomes.
Chaplin Steve, Birkedal Maj Friberg, Crilly Erica, Fletcher Simon, Garcia Sara, Mulders Greta, Myrin-Westesson Linda, Pollard Debra, Sanigorska Anna, Uitslager Nanda   +9 more
doaj   +1 more source

The use of rIX-FP in patients with haemophilia B: a nurse's perspective

The Journal of Haemophilia Practice, 2021
The management of patients with haemophilia is complex and requires lifelong care to be delivered by a specialist multidisciplinary team. Haemophilia B results from a deficiency or absence in coagulation factor IX (FIX), leading to easy bruising, and ...
Garner Kara, Guelcher Christine, Pollard Debra   +2 more
doaj   +1 more source

Design of a Prospective Study on Pharmacokinetic-Guided Dosing of Prophylactic Factor Replacement in Hemophilia A and B (OPTI-CLOT TARGET Study)

TH Open, 2022
In resource-rich countries, almost all severe hemophilia patients receive prophylactic replacement therapy with factor concentrates to prevent spontaneous bleeding in joints and muscles to decrease the development of arthropathy and risk of long-term ...
Tine M.H.J. Goedhart, Laura H. Bukkems, Michiel Coppens, Karin J. Fijnvandraat, Saskia E.M. Schols, Roger E.G. Schutgens, Jeroen Eikenboom, Floor C.J.I. Heubel-Moenen, Paula F. Ypma, L. Nieuwenhuizen, K. Meijer, Frank W. G. Leebeek, Ron A.A. Mathôt, Marjon H. Cnossen   +13 more
doaj   +1 more source

Web-based Application for the Population Pharmacokinetic Service (WAPPS)'s impact on dosage selection: a single paediatric centre experience

The Journal of Haemophilia Practice, 2021
Current treatment for severe haemophilia includes prophylactic factor replacement to prevent bleeding. Coagulation factor products have significant inter-patient variability in pharmacokinetic (PK) parameters.
Kwan Celia, Bhatt Mihir D., Strike Karen, Decker Kay, Matino Davide, Chan Anthony K.C.   +5 more
doaj   +1 more source

A Case of Heel Reconstruction with a Reverse Sural Artery Flap in a Hemophilia B Patient

Archives of Plastic Surgery, 2012
Hemophilia B is a rare blood coagulation disorder. Complications such as bleeding and hematoma can cause necrosis of flaps, wound disruption, and the disturbance of wound healing.
Byung Kwon Lee, Jeong Su Shim
doaj   +1 more source

Identification of the Profile of the Patients with Hemophilia B Eligible for Treatment with Nonacog Alfa Once-Weekly

Reports, 2020
This study aimed to identify the characteristics of patients with hemophilia B eligible for once-weekly treatment with Nonacog alfa. Methods: A survey was conducted in 14 Hemophilia (HCs) of Italy.
Dorina Cultrera, Raimondo De Cristofaro, Paola Giordano, Silvia Linari, Silvia Macchi, Renato Marino, Angelo Claudio Molinari, Angiola Rocino, Cristina Santoro, Piercarla Schinco, Sergio Siragusa, Giuseppe Tagariello, Annarita Tagliaferri, Ezio Zanon, Massimo Morfini   +14 more
doaj   +1 more source

Minimal dataset for post-registration surveillance of new drugs in hemophilia: communication from the SSC of the ISTH [PDF]

, 2017
Clinical ...
Collins, P., Iorio, A., Lillicrap, D., Makris, M., Peyvandi, F., Pipe, S.W., Rosendaal, F.R., Subcomm Factor VIII Factor IX   +7 more
core   +3 more sources